Tag Archives: OMP-131R10

Targeting Cancer Stem Cells – OncoMed’s R-SPONDIN LGR Antibody for Colorectal Cancer

OncoMed initiated a Phase I/II trial of its anti-RSPO3 antibody (OMP-131R10) in patients with relapsed colorectal cancer. Patients will also be receiving FOLFIRI (5-FU, irinotecan, leucovorin). Continue reading